CXCR2 Inhibition Combined With Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer
PLoS ONE - United States
doi 10.1371/journal.pone.0139237
Full Text
Open PDFAbstract
Available in full text
Categories
Date
September 28, 2015
Authors
Publisher
Public Library of Science (PLoS)